连花清瘟颗粒联合磷酸奥司他韦胶囊治疗流行性感冒患者的临床效果

目的探讨连花清瘟颗粒联合磷酸奥司他韦胶囊治疗流行性感冒患者的临床效果。方法选取2019年12月至2020年2月沈阳市第五人民医院收治的147例流行性感冒患者作为研究对象,将患者按照治疗方案不同分为观察组(77例)和对照组(70例)。两组患者给予磷酸奥司他韦胶囊口服治疗,在此基础上给予观察组患者采用连花清瘟颗粒治疗,两组治疗5 d。比较两组患者治疗前后炎症介质与免疫因子水平,两组患者退热时间,咳嗽、咽痛和肌肉酸痛消失时间,记录不良反应发生情况。结果治疗前两组患者C反应蛋白(CRP)、白细胞介素-6(IL-6)、CD4+/CD8+水平比较,差异无统计学意义(P>0.05);治疗后,两组患者CRP、IL-6明显降低,CD4+/CD8+升高,观察组各项指标改善优于对照组,差异有统计学意义(P<0.05)。观察组患者退热时间,咳嗽、咽痛和肌肉酸痛消失时间明显短于对照组,差异有统计学意义(P<0.05)。观察组与对照组患者治疗过程中出现1例腹泻、1例恶心呕吐、1例神经系统症状,不良反应发生率分别为3.9%(3/77)、4.3%(3/70),两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论使用连花清瘟颗粒联合磷酸奥司他韦胶囊治疗流行性感冒,可有效改善患者炎症介质、免疫因子水平,患者能在更短时间内退热,快速消除咳嗽、咽痛和肌肉酸痛等不适症状,安全性高,是临床治疗流行性感冒的合理方案。

Clinical Effect of Lianhua Qingwen Granule Combined with Oseltamivir Phosphate in the Treatment of Patients with Influenza

Objective To explore the clinical effect of Lianhua Qingwen Granule combined with oseltamivir phosphate in the treatment of patients with influenza. Methods A total of 147 patients with influenza admitted to Shenyang Fifth People’s Hospital from December 2019 to February 2020 were selected as the research objects and were divided into an observation group and a the control group according to different treatment regimens;both groups were treated with oseltamivir phosphate orally, on this basis, the observation group was given Lianhua Qingwen Granule. Both groups were treated for 5 days. The levels of inflammatory factors and immune factors before and after treatment were compared between the 2 groups, the duration of antipyretic fever, cough, sore throat and muscle soreness disappeared in both groups, and the occurrence of adverse reactions was recorded. Results There was no significant difference in the levels of C-reactive protein(CRP), interleukin-6(IL-6), and CD4+/CD8+ between the 2 groups before treatment(P>0.05);after treatment, the CRP and IL-6 significantly decreased, and CD4+/CD8+ increased. The improvement of various indicators in the observation group was better than that of the control group, and the difference was statistically significant(P<0.05). The disappearance time of fever, cough, sore throat and muscle aches in the observation group was significantly shorter than that in the control group, and the difference was statistically significant(P<0.05). The observation group and the control group had 1 case of diarrhea, 1 case of nausea and vomiting, and 1 case of neurological symptoms during treatment. The incidence of adverse reactions was 3.9%(3/77) and 4.3%(3/70) respectively. The difference was not statistically significant in the comparison of the incidence of adverse reactions between the 2 groups(P>0.05). Conclusion Lianhua Qingwen Granule combined with oseltamivir phosphate capsule in the treatment of influenza can better improve the level of inflammatory factors and immune factors in patients. Patients can reduce the fever in a shorter time and eliminate symptoms such as cough, sore throat and muscle soreness, with good security. It is a reasonable plan for clinical treatment of influenza.